Loading…
Loading…
ImmunityBio (IBRX) reported earnings 30 days ago. What's next for the stock?
ImmunityBio is rated a strong buy, driven by ANKTIVA's FDA approval for BCG-unresponsive NMIBC and significant pipeline expansion potential. Current valuation reflects success in bladder cancer and BCG-naïve expansion, but assigns limited value to systemic immunotherapy potential in NSCLC or other types of cancer. Key near-term catalysts include phase 3 NSCLC data and BCG-naïve bladder cancer trial results, both of which could unlock substantial upside.
Canada Pension Plan Investment Board acquired a new position in shares of ImmunityBio, Inc. (NASDAQ: IBRX) during the undefined quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 70,200 shares of the company's stock, valued at approximately $615,000. A number
ImmunityBio, Inc. (IBRX) Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit - Contact Kessler Topaz Meltzer and Check
Did you buy CAPR securities between December 17, 2025 and July 26, 2026? Affected CAPR Investor Summary Who: Capricor Therapeutics, Inc. (NASDAQ: CAPR) What: Securities fraud class action lawsuit filed Class Period: December 17, 2025 through July 26, 2026 Deadline to Seek Lead Plaintiff Status: September 28, 2026 Key Lawsuit Allegations: Material misstatements and/or omissions concerning the company's lead product candidates statistical analysis plan and FDA compliance Investor Action: Contact Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) for recovery options RADNOR, Pa.
Bell and Brown Wealth Advisors LLC purchased a new stake in ImmunityBio, Inc. (NASDAQ: IBRX) in the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund purchased 75,050 shares of the company's stock, valued at approximately $657,000. A number of other large investors have also
Bank of America Corp DE grew its stake in shares of ImmunityBio, Inc. (NASDAQ: IBRX) by 2.7% in the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 2,447,843 shares of the company's stock after purchasing an additional 65,340 shares during the quarter. Bank of
CULVER CITY, Calif.--(BUSINESS WIRE)--ImmunityBio, Inc. (NASDAQ: IBRX), a commercial-stage immunotherapy company, today announced that Dr. Jim Yong Kim has joined the company as Vice Chairman. Dr. Kim will serve in a newly created Office of the Executive Chairman, where he will focus on strengthening the company's international and global relationships. He will report to Executive Chairman and Founder Dr. Patrick Soon-Shiong. The Office of the Executive Chairman will bring together senior leade.